Skip to content
DataLookout
Menu

NCT06660381

Psilocybin-assisted Treatment for Cannabis Use Disorder

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 24 words Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Study completion pushed from Dec 2026 to Feb 2027
    • Primary completion date changed from estimate of Nov 2026 to Oct 21, 2026
    • Secondary endpoints: details revised at 2 of 2 entries
    • Site details revised
  2. Notable Primary completion date: Mar 2026 to Nov 2026
    • Study completion date: Sep 2026 to Dec 2026
    v4
  3. Minor Secondary endpoints: details revised at 2 of 2 entries
    • Study description revised
    v3
  4. Minor Primary completion date: Dec 2025 to Mar 2026
    • Study completion date: Jun 2026 to Sep 2026
    • Start date changed from estimate of Nov 2024 to Nov 8, 2024
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Self-reported cannabis use as assessed by a modified Timeline Follow-Back interview
Timeframe: Baseline, weekly up to 3 months
Biomarkers of recent cannabis use
Timeframe: Baseline, 3 months

Secondary (2)

Beck Depression Inventory-II (BDI-II) score
Pittsburgh Sleep Quality Index (PSQI) score

Arms and interventions

PsilocybinExperimental

Open-label psilocybin will be administered with psychological support to each participant at two dosing sessions approximately 2 weeks apart.

Drugs: Psilocybin

Sites

1 site in 1 country

  • Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States